A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.

"Declarations Ethics approval and consent to participateThis clinical trial was conducted at a single academic medical center (The University of Texas MD Anderson Cancer Center). The clinical trial was approved by the Institutional Review Board and was conducted in accordance with the Declaration of Helsinki. All participants signed informed consent. Competing interestsN.J.S. and E.J. have received research funding and honoraria from Takeda Oncology. The rest of the authors have no relevant conflicts to disclose. Competing interests N.J.S. and E.J. have received research funding and honoraria from Takeda Oncology. The rest of the authors have no relevant conflicts to disclose."

"Funding This research is supported in part by the MD Anderson Cancer Center Leukemia SPORE CA100632 and the NIH/NCI Cancer Center Support Grant P30 CA016672. N.J.S. was supported by the American Society of Hematology Clinical Faculty Award for this project. Takeda Oncology provided research funding and free pevonedistat."

"Trial registration ClinicalTrials.gov (NCT03862157)."